**Name of Journal:** World Journal of Clinical Cases

**Manuscript NO:** 77911

**Manuscript Type:** CASE REPORT

**Abstract**

**BACKGROUND**

Vitamin K$_1$ (phytomenadione) is a fat-soluble naturally occurring vitamin that is widely used to treat certain coagulation disorders. Adverse cutaneous reactions to vitamin K$_1$ can occur; however, owing to its low incidence and considerable variability in presentation and morphology, its diagnosis can be easily overlooked. Managing these reactions may be challenging for patients and clinicians. Therefore, reviewing the adverse cutaneous reactions to vitamin K$_1$ is important.

**CASE SUMMARY**

Here we report the case of a 50-year-old woman with no pre-existing hepatic disease who developed a cutaneous allergic reaction to subcutaneous vitamin K$_1$ that presented as localized eczematous plaques at the vitamin K$_1$ injection site. The eruption developed within 5 days of the injection and persisted for 32 mo despite treatment with topical and intralesional steroids. Eczema was diagnosed based on the results of the pathological examination, immunohistochemical staining, and a skin biopsy. The patient was advised to take herbal medicines orally twice daily. After treatment and follow-up, the patient’s eczematous urticarial plaques improved and her condition stabilized.
CONCLUSION
Here we present the first case of a cutaneous allergic reaction to subcutaneous vitamin K₁ that was successfully treated with Chinese medicine.

**Key Words:** Vitamin K₁; Subcutaneous injection; Adverse reactions; Herbal medicine; Polyoxymethylated castor oil; Case report guidelines; Case report


**Core Tip:** Adverse cutaneous reactions to vitamin K₁ can occur; however, their diagnosis can easily be overlooked. Managing these reactions may be challenging for both patients and clinicians. Here we report a patient who developed a cutaneous allergic reaction to subcutaneous vitamin K₁ that was successfully treated with herbal medicine, suggesting that Chinese medicine therapy may be a feasible way to treat adverse cutaneous reactions. We confirmed our clinical findings through physical examination, a skin biopsy, and immunohistochemical staining. We also conducted a literature review of eczematous-type reactions to clarify the possible pathogenesis and provoke new thinking regarding the clinical treatment of this disease.
INTRODUCTION

Vitamin K₁, currently available for oral, intramuscular, subcutaneous, or intravenous administration, is generally well tolerated[1]. However, adverse effects of vitamin K₁ have rarely been observed and were mostly reported in the early 1960s in the European literature. The most important adverse effects of vitamin K₁ are hyperbilirubinemia and kernicterus in newborn infants[2], particularly in premature infants resulting from the competition for glucuronyl transferase in the presence of immature liver function[3].

Based on the characteristics of skin rashes, three types of adverse events can be caused by vitamin K₁ injection: (1) localized pruritic erythematous, eczematous, indurated plaques (most common); (2) localized morphea-form eruptions (secondary to the eczematous type[4-8]); and (3) diffuse maculopapular eruptions (very rare), which were reported in early studies[9-11]. In accordance with the case report guidelines[12], here we present a case of a patient who developed an eczematous-type reaction to vitamin K₁ injection. Residual pigmentation persisted after 18 mo of treatment; however, the patient responded well to treatment with Chinese medicine (CM).

Cutaneous reactions caused by vitamin K₁ injections are mainly treated symptomatically. Most patients are treated with topical corticosteroids with or without occlusion and intralesional steroids; however, these treatments are ineffective. The topical application of tacrolimus (FK-506), a potent interleukin-2 and T-cell activation inhibitor, may become a future treatment option. Lauherma[13] demonstrated that topical tacrolimus pretreatment effectively suppresses allergic contact dermatitis caused by dinitrobutylphenol. However, its use for treating cutaneous hypersensitivity reactions to vitamin K₁ has not been reported.

Some researchers believe that the exacerbation of persistent eruptions may be related to dietary vitamin K. However, no follow-up investigation of this possibility is available in the English literature. This is probably due to difficulty avoiding dietary vitamin K₁, as small quantities are present in many different foods, with high concentrations in green leafy vegetables. Our patient failed to maintain a low vitamin K₁ diet due to food
preferences. Hence, whether the minute quantities of vitamin K present in some foods preclude the efficacy of dietary therapy remains unknown.

**CASE PRESENTATION**

*Chief complaints*

A 50-year-old woman was referred to our hospital on September 14, 2020 with the complaint of an intensely pruritic erythematous patch on her right hip.

*History of present illness*

The patient’s symptom of an intensely pruritic erythematous patch started 1 year before presentation.

*History of past illness*

One year prior, the patient had received subcutaneous injections of vitamin K 40 mg before thyroid nodule surgery to prevent bleeding. Five days after the injections, she developed the abovementioned symptoms at the injection site that caused discomfort without any obvious burning, pain, or other problems. She had not been treated with phytonadione, cyclosporine, or other medications containing polyoxyethylated castor oil (PEO-CO). She was diagnosed with urticaria, for which topical chloramphenicol betamethasone liniment, dexamethasone sodium phosphate, and chlorpheniramine maleate injections were prescribed. However, her condition did not improve substantially. Despite intermittent treatment for one year, her condition was not well controlled.

*Personal and family history*

The patient denied any family history of any hereditary disease.

*Physical examination*
A physical examination revealed an erythematous itchy-infiltrated area of approximately 10 cm × 10 cm on the right hip at the injection sites. The patient had a dry mouth, no sweat, and normal urine and bowel movements. Her tongue was red and covered with a thin and greasy coating, and her pulse was fine and rapid. Since the onset of the disease, she had no fever, chills, joint pain, swollen lymph nodes, weight loss, trauma, foreign body contact, or suspicious drug use. Her clinical symptoms of intense pruritus and weeping, erythematous, eczematous, and indurated plaques are shown in Figure 1A and B.

**Laboratory examinations**

Liver ultrasonography findings and aspartate aminotransferase (serum glutamic oxaloacetic transaminase), alkaline phosphatase, and serum bilirubin levels were normal.

**Skin biopsy**

A clear diagnosis of the disease could not be made based on the clinical manifestations of the erythematous and eczematous plaques. The patient’s skin lesions were nonspecific and could be easily confused with mycosis fungoides (MF). To ensure diagnostic accuracy, we performed a biopsy of the skin from the right hip during the examination, the results of which were available within a week. Considering the characteristics of the skin lesions, we temporarily suspected an adverse cutaneous reaction to vitamin K₃ (eczematous type), and the CM diagnosis was “wet sores.” The tongue coating, pulse, and skin lesion characteristics were consistent with those of blood-heat syndrome. We considered blood heat and Yang floating as the main pathogeneses according to the CM theory.

**Histological examination**

The erythema area was reduced, the degree of itching was alleviated, and the patient’s condition gradually stabilized by November 12, 2020. The patient’s tongue was reddish
with a white and greasy coating and her pulse was slippery. A skin biopsy was performed (Figure 1C and D), and a histological examination showed an intense perivascular infiltrate composed of lymphocytes and histiocytic cells with rare plasma cells and eosinophils. Prominent endothelial cell swelling was also observed. The infiltrate extended through the reticular dermis into the subcutaneous fat and focally surrounded the eccrine and neural structures. The lower half of the dermis was markedly sclerotic with thickened eosinophilic collagen bundles. These findings were consistent with our diagnosis.

FURTHER DIAGNOSTIC WORK-UP
A microscopic examination revealed a normal epidermis and more lymphocytes infiltrating the blood vessels in the dermis, several of which mimicked Pautrier microabscesses (Figures 1E and F). Immunohistochemical (IHC) staining showed that T cells were positive for CD3, CD5, and CD4 and partially positive for CD8 (Figure 2A–D). B cells were positive for CD20 and CD79a (Figure 2E and F). Histocytes were positive for CD68, natural killer cells were positive for CD56, and mastocytes were negative for CD117 (Figures 3A–C). B cells tested positive for common acute lymphoblastic leukemia antigen (CD10), negative for platelet-endothelial cell adhesion molecule-1 was negative for (CD31), and negative for syndecan-1 (CD138) (Supplementary Figure 1). We ruled out MF because the IHC results suggested that the cells in this case were multi-lineage and polyclonal.

FINAL DIAGNOSIS
According to the clinical picture, histopathology results, and IHC results, the final diagnosis was a cutaneous allergic reaction to the vitamin K1 injections.

TREATMENT
The patient was treated with an oral herbal medicine for "cooling blood and restraining Yang" twice daily, 30 min after meals. Our team previously reported that blood-cooling
and Yang-restraining herbs had a positive clinical effect in the treatment of skin diseases such as blood-heat syndrome, eczema, and psoriasis vulgaris\textsuperscript{[14,15]}. Other authors showed that the drug for cooling blood and restraining Yang may upregulate the expressions of PD-1 mRNA, PD-L2 mRNA, and their proteins in patients with psoriasis vulgaris, which manifests as blood-heat syndrome\textsuperscript{[16]}. The specific compositions, dosages, and medicinal sources of these herbal decoctions are listed in Table 1.

OUTCOME AND FOLLOW-UP

The previous misdiagnosis was corrected in a timely manner. Nevertheless, the main components of the blood-cooling and yang-restraining herbal medicine remained unchanged. The dose of the drug was adjusted appropriately, and the patient continued to reduce her intake of leafy green vegetables.

The patient was followed up on June 23, 2021, January 6, 2022, and April 2, 2022. After taking the herbal medicine, the patient’s erythema area was reduced, the degree of itching was alleviated, and her symptoms improved significantly. Her tongue was still red with a thin and greasy coating and her pulse was fine and rapid; hence, the composition of the herbal medicine was adjusted accordingly. After taking the herbal medicine for 18 mo, her symptoms greatly improved with only a few residual pigments in the lesion area and no itching sensation. She stopped taking the oral herbal medicine in April 2022 in accordance with the doctor’s advice.

At presentation, the patient showed some inconspicuous pigment residues with no itching sensation, and the lesions did not involve the internal organs or lymph nodes. Throughout the treatment and follow-up period, the patient showed good adherence to and tolerance of the CM therapy, and no adverse or unanticipated events occurred during this period. The patient’s condition was well controlled, and her quality of life improved. She was regularly followed up at a local clinic, with no complaints of discomfort or adverse events during treatment. At the 18-mo follow-up, the eczematous erythema plaques on her right hip had notably improved compared to the pretreatment condition. However, the eruption persisted with occasional pruritus for approximately
32 mo. The patients’ skin lesions before and after treatment are shown in Figures 4A and B. The full timeline of diagnosis, medical treatment process, physical examination findings, clinical characteristics, and laboratory findings are shown in Figure 5.

**DISCUSSION**

Our patient developed severe localized reactions at the site of the subcutaneous injections of vitamin K1, and the lesions slowly subsided over a 32-mo period. Although the early changes resembled urticaria, they were not transient. Most importantly, the swollen red plaques involved underlying dermal involvement and epidermal changes. The diagnosis was confirmed by clinical imaging, histopathology, and IHC staining. The persistence of the pruritus in our patient may imply that the drug may have remained locally at the injection site or that an altered host tissue reaction in the skin may have provided a continued antigen stimulus.

We summarized the results of the 20 cases reported to date of eczematous-type reactions in Table 2, including the administration route, dose, reaction, and diagnostic assessment, with the aim of determining the pathogenesis of this hypersensitivity. Several features of the eczematous reaction to vitamin K1 suggest that it was a manifestation of delayed-type hypersensitivity, a prototype of type IV cell-mediated immunity. In most cases, lesions appeared approximately 7-10 d after the first dose of vitamin K1[17-36]. In addition, subsequent patch and intradermal testing produce a reaction within 3-5 and 1-2 d, respectively[17-21,23,25,26,31,32,34,36]. The time sequence of the development of these reactions corresponded well with type IV cell-mediated hypersensitivity. The positive results of sensitivity testing using patch test methods implied that sufficient antigens may have been absorbed to generate an immune response. Several patients exhibited a recall reaction[21,23,30] in previously affected areas compatible with the recall phenomenon in allergic contact eczema when antigens applied in new areas precipitate an eczematous flare-up. Several histopathological studies of biopsy specimens from the lesion and the intracutaneous test site showed spongiosis of the epidermis, dermal edema, and perivascular mononuclear and
eosinophilic cellular infiltrates consistent with delayed-type hypersensitivity\cite{18,20,25,27,31,33,36}.

To identify the allergen, we summarized the reported cases that used patch and intradermal testing to delineate the mechanism of skin hypersensitivity to vitamin K₁. Previous studies consistently reported that only the whole preparation of vitamin K₁ (in its vehicle) or vitamin K₁ alone produced positive test results\cite{19,21}. When the individual components of the vehicles were tested, they almost always yielded negative results. In some cases, patch tests showed negative results, while intradermal tests showed opposite results\cite{25,30}, which may, to some degree, reflect insufficient percutaneous absorption. Page et al\cite{37} found that dermatitis from topically applied vitamin K₁ was caused by the chemical rather than the base. One study in Australia\cite{32} illustrated the importance of testing with appropriate concentrations of reagents, as patch testing with Konakion Cremophor-EL 2 mg/mL showed a negative result, whereas testing with a 10 mg/mL concentration (the concentration administered at hospitals) showed a strongly positive result. Another study showed relatively high rates of intradermal positivity in control participants (4 of 10 controls)\cite{29}; however, the reactions in controls were not as florid, and in two cases, the reaction was delayed to day 6, which may indicate sensitization.

Previous reports suggested that the underlying cause of the reaction is not phytonadione but rather the vehicle, PEO-CO, which is used as a solubilizer or diluent for several drugs. Although experimental and clinical data are limited, these reactions have been classified as anaphylactoid reactions\cite{38}. Experimental and other evidence suggested that PEO-CO may cause anaphylaxis by releasing histamine, as demonstrated by studies showing its pharmacological action in dogs\cite{39}, a memory-mediated reaction involving complement activation\cite{40}, and the presence of immunoglobulin G steroid sulfatase antibodies as confirmed by appropriate immunological tests\cite{41}. However, PEO-CO may not be responsible for all anaphylactic events, as demonstrated by two cases of anaphylaxis after the administration of formulations that did not containing PEO-CO\cite{42,43}. 

Several vitamin K preparations are available that contain different inactive ingredients. Most previous investigators did not use patches or intracutaneous testing for these additional ingredients of vitamin K₁. Five investigators tested the components of their particular preparations and obtained negative results\cite{19,21,23,25,30}. These results suggest that the antigen that causes adverse cutaneous reactions is not the inactive ingredient in the mixture but vitamin K itself. Because of the potential for exacerbating the long-lived reactions in our patient, no patch or intracutaneous tests were performed.

Liver disease was previously believed to play a role in the pathogenesis of this allergic reaction\cite{44}; however, six cases of cutaneous reactions to vitamin K₁ have been described in patients with no known liver disease\cite{21,24,25}. One study in Japan showed, in 94 documented cases of cutaneous hypersensitivity reactions to vitamin K₁, no correlation between vitamin K₁ hypersensitivity and liver disease\cite{30}. Nevertheless, as patients with liver disease account for the majority treatment demand for vitamin K₁, they may be at an increased risk of developing cutaneous reactions to it. An investigation into the underlying liver dysfunction may be indicated when a patient develops a local eczematous reaction to vitamin K₁.

In all reported cases of skin reactions, the dose range was 10-1750 mg\cite{17-36}. One study\cite{20} hypothesized that even a minimum dose can cause an eruption. Some researchers have noted that patients in some of the more recalcitrant cases received the smallest doses\cite{33}. In addition, the dosage of vitamin K seems to have no correlation with the onset of the allergic reaction as confirmed by a study\cite{45} that described sclerodermatous reactions associated with large doses of vitamin K₁ 100-500 mg. This finding suggests that neither injections nor large doses are required for a sclerodermatous reaction to occur\cite{46}. Our patient had no evidence of preexisting hepatic disease and received a total dose of 40 mg.

**CONCLUSION**

Although the incidence of adverse reactions to the subcutaneous injection of vitamin K₁ is considerably low, such adverse effects can be devastating. In our case, the patient
experienced discomfort only in the area of the local lesions and the disease did not have a particularly serious impact on her daily life. Overall, the disease progressed slowly and was well controlled from onset to follow-up. However, it remains difficult to make an accurate clinical conclusion about this case of hypersensitivity, which creates new challenges and requirements for the diagnosis and treatment of such conditions that, in the future, may be avoided with a more judicious use of this form of vitamin K₁ in the clinical setting. In contrast to the previously reported cases, our patient was treated its CM. The key to CM treatment is to accurately identify the syndrome and treat the symptoms. CM may achieve unexpectedly good results in terms of improving the patient’s condition. However, the efficacy, safety, and mechanisms of CM therapy require further investigation. Additionally, whether CM therapy alone or combined with Western medicine has better clinical efficacy for the treatment of these adverse reactions requires confirmation.
| 1 | Karl Wilkins, Joel DeKoven, Dalai Assaad. "Cutaneous Reactions Associated with Vitamin K", Journal of Cutaneous Medicine and Surgery, 2016 | 165 words — 5% |
| 2 | Deanna A Wong. "Cutaneous allergic reaction to intramuscular vitamin K1", Australasian Journal of Dermatology, 8/1999 | 100 words — 3% |
| 3 | H.M. BARNES, I. SARKANY. "Adverse skin reaction from vitamin KI", British Journal of Dermatology, 1976 | 56 words — 2% |
| 5 | www.ncbi.nlm.nih.gov | 45 words — 1% |
| 6 | "Syndrome Differentiation and Treatment for Common Conditions", World Century Compendium to TCM A 7-Volume Set, 2013. | 35 words — 1% |
| 7 | www.wjgnet.com |


Sabine Sommer. "Type IV hypersensitivity to vitamin K", Contact Dermatitis, 2/2002

Vanessa Mh Lo, Ck Ching, Albert Y.W. Chan, Tony W.L. Mak. "Bromadiolone toxicokinetics: Diagnosis and treatment implications", Clinical Toxicology, 2008

Jia-Yan Huang, Rui Yang, Jia-Wu Li, Qiang Lu, Yan Luo. "Cavernous hemangioma of an intrapancreatic accessory spleen mimicking a pancreatic tumor: A case report", World Journal of Clinical Cases, 2022